Selank
A synthetic tuftsin analog studied for neurobehavioral effects, with a small and geographically concentrated evidence base.
On this page
WHAT THE EVIDENCE SAYS
Selank evidence summary.
Selank's human evidence is small and geographically concentrated. It is not a U.S.-approved anxiety treatment and should not be treated as equivalent to established therapies.
01 / CLASSIFICATION
What is Selank?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
Selank human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
Selank FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is Selank being studied for?
05 / COMPARISONS
Compare Selank.
06 / LATEST & DEFINING SOURCES
Selank primary and official sources.
07 / QUESTIONS
Questions about Selank.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
Selank's human evidence is small and geographically concentrated. It is not a U.S.-approved anxiety treatment and should not be treated as equivalent to established therapies.
Current source-backed research areas include Anxiety, Neurotransmission, Tuftsin analogs, Neuroimmune signaling. These areas describe investigation, not established personal benefit.
Current U.S. status for Selank: No FDA-approved Selank drug product; FDA identifies immunogenicity and peptide-impurity concerns for compounded Selank acetate products.
Current sport-status snapshot for Selank: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
Active-comparator studies without broad replication do not settle comparative effectiveness or long-term safety.